CUPERTINO, Calif., Nov. 2, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has been awarded grants totaling $733,438 to advance our programs in post-operative pain relief, attention deficit disorder (ADHD) and chronic diseases treated with biologic agents. The grants are being awarded under the Patient Protection and Affordable Care Act […]
CUPERTINO, Calif., Oct 27, 2010 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:
DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call Read More »
CUPERTINO, Calif., Sep 7, 2010 (GlobeNewswire via COMTEX) — DURECT Corporation (Nasdaq:DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. — Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled “FDA Regulations and Testing for Pain Products” at the National Conference on Pain for Frontline Practitioners
DURECT Corporation to Participate in Upcoming Healthcare Conferences Read More »
CUPERTINO, Calif., Aug 04, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three
DURECT Corporation Announces Second Quarter 2010 Financial Results Read More »
CUPERTINO, Calif., July 29, 2010 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo:
DURECT Corporation Invites You to Join Its Second Quarter 2010 Earnings Conference Call Read More »
CUPERTINO, Calif., July 28, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5 at 1:45 p.m. Eastern Time. The conference is being held at the Sheraton New York
DURECT to Present at the BMO Capital Markets Focus on Healthcare Conference Read More »
CUPERTINO, Calif., July 1, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has secured a committed equity financing facility under which it may sell up to $50 million of its registered common stock to Azimuth Opportunity Ltd. for a term of 24 months. DURECT is not obligated to utilize any
DURECT Corporation Secures $50 Million Committed Equity Financing Facility Read More »
CUPERTINO, Calif., June 16, 2010 /PRNewswire via COMTEX/ –DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under development for the treatment of post-surgical pain. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) This hysterectomy trial
CUPERTINO, Calif., June 7, 2010 /PRNewswire via COMTEX/ –In conjunction with the announcement of a POSIDUR(TM) (SABER(TM)-Bupivacaine) collaboration between DURECT Corporation (Nasdaq: DRRX) and Hospira, Inc. (NYSE: HSP), you are invited to listen to a conference call that will be broadcast live over the internet on Monday, June 7, 2010 at 5:00 pm Eastern Time
— Product would strengthen Hospira’s acute-care portfolio, offer novel pain treatment — LAKE FOREST, Ill., and CUPERTINO, Calif., June 7, 2010 — Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, and DURECT Corporation, a specialty pharmaceutical company (Nasdaq: DRRX), today announced that the companies have entered into a licensing agreement to
